Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03242824 · ClinicalTrials.gov registry record · Phase 2
The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03242824: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03242824 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03242824, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This proposal is for a pilot study comparing volumes of 18F-DOPA-PET avidity with contrast enhancement and T2 FLAIR on MRI. Investigators then plan to compare patterns of failure with target volumes, pre-treatment MRI changes and pre-treatment 18F-DOPA-PET.
Interventions
- PROCEDURE Positron Emission Tomography
- RADIATION Intensity-Modulated Radiation Therapy
- DRUG Fluorine F 18 Fluorodopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-09-29 |
| Est. Completion | 2021-06-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03242824
The ClinicalTrials.gov registry entry for NCT03242824 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Positron Emission Tomography is the first listed.
NCT03242824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03242824 about?
NCT03242824 is a clinical study titled "The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma". This proposal is for a pilot study comparing volumes of 18F-DOPA-PET avidity with contrast enhancement and T2 FLAIR on MRI. Investigators then plan to compare patterns of failure with target volumes, pre-treatment MRI changes and pre-treatment 18F-DOPA-PET.
What is the current status of trial NCT03242824?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2017-09-29. Estimated completion is 2021-06-16.
What interventions are being tested in trial NCT03242824?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Intensity-Modulated Radiation Therapy (RADIATION), Fluorine F 18 Fluorodopa (DRUG).
Who is sponsoring clinical trial NCT03242824?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.